EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Combining Network Pharmacology, Molecular Docking and Experimental Validation to Explore the Effects and Mechanisms of Indirubin on Acute Lymphoblastic Leukemia

Lu Jin, Yunshuang Guan, Xue Li, Mingyue Wang, Ying Shen, Nianxue Wang, Zhixu He

Drug Design, Development and Therapy · 2025-02 · Volume 19 · 1083-1103

DOI: 10.2147/dddt.s500249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025-02. Verfasst von Lu Jin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, School of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, People's Republic of China. Hauptthemen laut MEDLINE: Molecular Docking Simulation, Network Pharmacology, Indoles, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To investigate the effects and underlying mechanisms of indirubin in treating ALL using network pharmacology and experimental validation.

Methods

Potential targets of indirubin- and ALL-related genes were identified using public databases. Core genes were filtered through protein-protein interaction analysis in Cytoscape. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were conducted to explore the potential mechanisms of indirubin against ALL. Drug-disease-functional annotation-signaling pathway network maps were constructed. Molecular docking between indirubin and core proteins was performed using AutoDock Vina software. Finally, both in vitro and in vivo experiments were performed to validate these findings.

Results

PPI network analysis identified eight potential core targets of indirubin in ALL: AKT1, CASP3, and the mammalian target of rapamycin. GO and KEGG enrichment analyses suggested that the mechanism of action of indirubin against ALL involves multiple biological functions and signaling pathways, with the PI3K-AKT pathway likely playing a central role. Molecular docking findings further confirmed the strong binding affinity of indirubin for the core targets. Both in vitro and in vivo experiments demonstrated that indirubin inhibited ALL cell proliferation and induced cell cycle arrest and apoptosis; the underlying mechanism may involve the PI3K-AKT signaling pathway.

Conclusion

The action and mechanism of indirubin in ALL through network pharmacology, as well as in vivo and in vitro experimental validation were elucidated, offering new insights and potential therapeutic avenues for the treatment of ALL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Molecular Docking SimulationNetwork PharmacologyIndolesPrecursor Cell Lymphoblastic Leukemia-LymphomaAntineoplastic AgentsHumansCell ProliferationAnimalsMiceDrug Screening Assays, AntitumorApoptosisProto-Oncogene Proteins c-aktDose-Response Relationship, DrugProtein Interaction MapsSignal Transduction

Stichwörter der Autor:innen

acute lymphoblastic leukemiaexperimental validationindirubinmolecular dockingnetwork pharmacology

Substanzen

indirubinIndolesAntineoplastic AgentsProto-Oncogene Proteins c-akt

Autor:innen und Institutionen

  • Department of Pediatrics, School of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.
  • Department of Pediatric Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.
  • Department of Immunology, College of Basic Medical Sciences, Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.
  • Department of Central Laboratory, Guizhou Provincial People's Hospital, Guiyang, Guizhou, People's Republic of China.
  • Tissue Engineering and Stem Cell Experiment Center, Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.

Zitieren

APA

Jin, L., Guan, Y., Li, X., Wang, M., Shen, Y., Wang, N., & He, Z. (2025). Combining Network Pharmacology, Molecular Docking and Experimental Validation to Explore the Effects and Mechanisms of Indirubin on Acute Lymphoblastic Leukemia. Drug Design, Development and Therapy, Volume 19, 1083-1103. https://doi.org/10.2147/dddt.s500249

Vancouver

Jin L, Guan Y, Li X, Wang M, Shen Y, Wang N, et al. Combining Network Pharmacology, Molecular Docking and Experimental Validation to Explore the Effects and Mechanisms of Indirubin on Acute Lymphoblastic Leukemia. Drug Design, Development and Therapy. 2025;Volume 19:1083-1103. doi:10.2147/dddt.s500249

BibTeX
@article{Jin2025,
  author = {Jin, Lu and Guan, Yunshuang and Li, Xue and Wang, Mingyue and Shen, Ying and Wang, Nianxue and He, Zhixu},
  title = {Combining Network Pharmacology, Molecular Docking and Experimental Validation to Explore the Effects and Mechanisms of Indirubin on Acute Lymphoblastic Leukemia},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  volume = {Volume 19},
  pages = {1083--1103},
  doi = {10.2147/dddt.s500249}
}
Kostenlos starten →